EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Galmed Pharmaceuticals Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 31, 2026
$2.85−0.00 (-0.00%)
Close on Oct 19, 2026
- Market cap
- $2.71M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Ownership
Who owns Galmed Pharmaceuticals's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Allen Baharaff | Chief Executive Officer, Director | 100,018 | 1.52% | Mar 18, 2026 |
| Guy Nehemya | Chief Operating Officer | 25,000 | 0.38% | Mar 18, 2026 |
| Yohai Stenzler | Chief Accounting Officer | 25,000 | 0.38% | Mar 18, 2026 |
| Doron Leib Cohen | Chief Financial Officer | 2,083 | 0.03% | Mar 18, 2026 |
| Brueck Liat Nissimov | Chief Scientific Officer | – | – | Mar 18, 2026 |
| Amir Poshinski | Director | 12,500 | 0.19% | Mar 18, 2026 |
| Carol L. Brosgart | Director | – | – | Mar 18, 2026 |
| Shmuel Nir | Director | 12,500 | 0.19% | Mar 18, 2026 |
| David Sidransky | Director | 1,042 | 0.02% | Mar 18, 2026 |